New diabetes clinical trial: Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

Published on: 2026-05-06T04:00:00Z
Conditions: Type 2 Diabetes; Obesity; Non-alcoholic Fatty Liver Disease
Interventions: Drug: CS0159; Drug: CS0159 placebo; Drug: Semaglutide
Sponsors: Shanghai Jiao Tong University School of Medicine
Not yet recruiting
https://ift.tt/pd9xFmf